Is there a risk of esketamine misuse in clinical practice?

In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for...

Full description

Saved in:
Bibliographic Details
Main Authors: Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman, Marta Torrens, Pablo Vega, Pilar Andres-Olivera, Francisco Javier Álvarez
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Drug Safety
Online Access:https://doi.org/10.1177/20420986241310685
Tags: Add Tag
No Tags, Be the first to tag this record!